Cite
HARVARD Citation
Uematsu, S. et al. (2023). Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021‐01). Thoracic cancer. 14 (2), pp. 168-176. [Online].